Tango Therapeutics (TNGX) Research & Development (2020 - 2026)

Tango Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $33.5 million for Q1 2026.

• On a quarterly basis, Research & Development fell 7.98% year-over-year to $33.5 million in Q1 2026; TTM through Mar 2026 was $129.3 million, a 9.16% decrease from a year earlier, with the FY2025 full-year figure at $132.2 million, down 8.17% from the prior year.
• Research & Development rose to $33.5 million in Q1 2026 per TNGX's latest filing, from $32.1 million in the prior quarter.
• Across five years, Research & Development topped out at $38.7 million in Q2 2024 and bottomed at $23.7 million in Q2 2022.
• The 5-year median for Research & Development is $31.3 million (2023), against an average of $31.2 million.
• Across the five-year window, Research & Development jumped 62.2% in 2022 and retreated 15.13% in 2025, its largest moves.
• Year by year, Research & Development stood at $29.1 million in 2022, then advanced by 7.73% to $31.3 million in 2023, then gained by 8.29% to $33.9 million in 2024, then declined by 5.41% to $32.1 million in 2025, then advanced by 4.46% to $33.5 million in 2026.
• Per Business Quant, the three latest TNGX Research & Development figures stand at $33.5 million (Q1 2026), $32.1 million (Q4 2025), and $30.8 million (Q3 2025).